A State Health Exchange Folds and Oncologists Fight Rising Drug Costs
This week in healthcare, Oregon drops its state exchange and oncologists work to battle rising costs.
On Friday, the state of Oregon’s exchange board voted to close its state-run exchange in favor of folding enrollees into Healthcare.gov. The Washington Post’s Wonkblog discusses some of the policy questions raised by the closure of an exchange.
As the healthcare realm continues to morph, will different generations of doctors handle it differently? According to this author, as Gen Xers and millennials start to take over we can expect fewer solo practices, more ACOs, and more emphasis on pay-for-value.
1. ASCO’s New Strategy to Define ‘Value’ in Cancer Care
2. Cost of Treatment May Influence Doctors
3. Comparative Effectiveness Studies of Cancer Drugs Is Costly
The American Society of Clinical Oncology (ASCO) has launched a strategic initiative to define value in cancer care. ASCO does not plan to release their algorithm to evaluate drug costs until this coming fall. See several perspectives on ASCO’s new initiative.
ACA’s ‘Pharma Tax’ Eyed as Key Factor in Sharp AWP Increase (with Chart: Rate of Rx Utilization Management in Exchange Plans vs. Employer Plans) [login required]
Average Wholesale Price (AWP), “a widely used industry benchmark for pricing pharmaceuticals, is forecast to grow dramatically in the coming years, according to some pharmacy benefit insiders who claim the 2010 Affordable Care Act’s (ACA’s) fee on brand drugmakers is a key reason behind the increases.” One response is management; a study found that exchange plans face utilization management about twice as often as employer plans.
In a panel discussion at the ACCC National Meeting, panelists discussed the costs and the value in cancer care, and how patients can participate. You can watch the full panel discussion video at the bottom of the page.
Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.